drugset
drugset / Trial / NCT04657965

LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

NCT04657965 ↗

Phase 0 Not yet recruiting 144 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

A study of LMP1 CAR-T for patients with LMP1 positive infectious diseases and hematological malignancies

Timeline

Start
2021-01-15
Primary completion
2024-01-15
Completion
2027-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject LMP1 CAR T-cells Cell therapy — Intravenous

Indications

hematopoietic and lymphoid cell neoplasm infectious disease